J&J's hepatitis C drug simeprevir gets nod from FDA staff before panel
This article was originally published in Scrip
Executive Summary
Johnson & Johnson’s hepatitis C drug simeprevir is effective and generally safe, though some patients should be screened before receiving the treatment, US FDA staff said in a report.